With a 1:8000 incidence, myotonic dystrophy type 1 (DM1), also known as Steinert’s disease, is the most common neuromuscular disease in adults. This autosomal, dominant disorder is caused by the expansion of a (CTG) _n_ triplet repeat in the 3′ untranslated region of the _DMPK_ gene. The manifestations of the disease include muscle wasting and weakness, myotonia, multiple endocrine disorders, respiratory insufficiency, early-onset cataract, cognitive impairment, and cardiac disease, including conduction defects, ventricular dysfunction, supraventricular, and ventricular arrhythmias.

See Editorial by Wheeler
See Clinical Perspective

The size of the CTG expansion, which may range from 50 to 4000 repeats, has been positively correlated with the global severity of the disease. The most severe clinical forms of the disease, such as congenital or early childhood DM1, have been exclusively observed in patients with the largest mutations. However, the relationship between CTG expansion size and cardiac manifestations of the disease remains unclear. Correlations with conduction system disease have been addressed in several studies, mainly with a cross-sectional design, showing contradictory findings.

Our objective was to study in a large cohort of DM1 patients the relationship between the size of the CTG expansion and (1) the prevalence of cardiac manifestations of the disease at initial presentation and (2) the long-term cardiac
outcome, with an analysis taking into account other confounding factors, such as age or sex.

Methods

The DM1-Heart Registry

The DM1-Heart Registry was designed and organized by the Cardiology Department of Cochin Hospital and the Neurological Unit of the Myology Institute at the Pitié Salpêtrière Hospital. We retrospectively included in this Registry consecutive patients >18 years old, admitted to our Institutions between January 2000 and December 2015 for the management of DM1, diagnosed by the presence of ≥250 CTG triplets in the 3′ untranslated region of the DMPK gene on blood leukocytes.

We retrospectively reviewed the patients’ medical records and entered the results of their genetic testing and all of their cardiac investigations in a dedicated database. During each yearly visit, a clinical examination, an ECG, and an echocardiography were performed. The vital status of patients who were not seen after December 2015 was ascertained by consulting the National Death Registry or by contacting their primary physician.

This study, which is in compliance with the ethical principles formulated in the declaration of Helsinki, was approved by our local Ethics Committee, and all patients, except those who had died before initiation of the study, granted their informed, written consent to participate in the Registry.

Patient Selection, Clinical Definitions, and Study End Points

Of the 1014 patients included in the Registry, only those who underwent genetic analysis at the time of the baseline cardiac investigations entered the final analysis (n=855 patients). Because CTG expansion is unstable and tends to increase during life, we studied the association between CTG expansion size and (1) the patient baseline characteristic, including the prevalence of cardiac manifestations of the disease and the findings of ECG and echocardiography, and (2) the lifetime occurrence of total death, sudden death, conduction system disease requiring the implantation of a permanent pacemaker, and supraventricular arrhythmias.

Conduction defect was defined as first-degree atrioventricular (AV) block, left or right bundle branch block, and left anterior or left posterior fascicular block on the surface ECG.15 According to the guidelines issued by the American Society of Echocardiography, the left ventricular (LV) dysfunction, measured by the Simpson’s biplane method, was considered abnormal when the LV ejection fraction was <55%.16

We classified sustained ventricular tachycardias as ventricular tachycardia or fibrillation based on the analysis of the cardiac rhythm during cardiopulmonary reanimation, or stored in the pacemaker memories, or both. A sustained ventricular tachycardia were classified as ventricular tachycardia when the ventricular rhythm was irregular and as a ventricular fibrillation when the rhythm was irregular and the rate >200 bpm.

Death was classified as sudden if it occurred unexpectedly (1) within 1 hour of onset of cardiac manifestations, in absence of prior hemodynamic deterioration, (2) during sleep, or (3) within 24 hours after the patient was last seen alive and apparently stable clinically.17 Indications for permanent pacing included third-degree AV block, type II second-degree AV block, sinus node dysfunction, and infranodal conduction defects with a HV interval >70 ms. HV interval is measured on the His bundle electrogram from beginning of the His deflection to the earliest identified ventricular activity on the surface ECG. Supraventricular arrhythmia was defined as a sustained atrial tachycardia with a duration of >30 second recorded on an ECG, a 24-hour ambulatory ECG, or in the memories of cardiac devices. Premature ventricular complexes were defined as >15 premature ventricular events per hour recorded on a 24-hour ambulatory ECG.18

Genetic Analysis

The size of CTG repeat analysis was expanded by Southern blot analysis. DNA was extracted from peripheral blood samples as previously reported. Ten microgram of DNA was digested using 2 restriction enzymes (EcoRI and BamHI) following the manufacturer’s conditions and electrophoresed on agarose gel (0.8%) for 24 hours at 50 V. The gel was depurinated, denatured, and neutralized, and the DNA fragments were transferred to a positive nitrocellulose membrane (Roche). Filter was hybridized to the (a-32P)-dCTP-labeled cDNA25 probe at 65°C for 18 hours. Before autoradiography, the filter was washed to a final stringency of 0.1×saline–sodium citrate, 0.1% sodium dodecyl sulfate at 65°C for 10 to 30 minutes. Since 2014, filters were probed with cDNA25 labeled using the nonradioactive PCR DIG probe synthesis kit (Roche). Probe hybridization and detection was made following the manufacturer’s conditions (DIG Easy Hyb, Anti-Digoxigenin AB, CDP Star; Roche).

Statistical Analysis

Continuous variables were expressed as median (interquartiles). Categorical variables were presented as frequencies and percent-ages. To analyze the relationship between CTG expansion size and patients’ characteristics at baseline, the continuous variable CTG expansion size was split into 4 quartiles, and comparisons were made using analysis of variance on ranks (Kruskall–Wallis test) followed by the Dunn’s test. The combining effects of age, sex, and CTG expansion size were taken into account by forcing these 3 variables into multivariate analyses: categorical variables were analyzed using logistic regression, and analysis of covariance was performed for continuous variables. For overall survival, sudden death, supraventricular and ventricular arrhythmia, and pacemaker implantation, Kaplan–Meier curves were constructed for each quartile of CTG expansion size, and curves were compared using the log-rank test. Then, we analyzed in 2 separate models the combining effects of (1) age, sex, CTG expansion size, and diabetes mellitus, and (2) all baseline characteristics using a multivariate Cox model for each end point. Statistical softwares used were Statview (version 5.0) and Sigmaplot (version 11.0). A value of P<0.05 was considered statistically significant.

Results

Study Population

From the 1014 adult patients with genetically proven DM1 of our registry, we identified and included in the present study 855 patients who underwent the quantification of the CTG expansion size at the moment of their baseline investigations. Their median age at initial presentation was 37 years (27–49), and 420 (49%) patients were male. The median mutation size was 530 repeats (300–830; additional Figure 1). Their baseline characteristics and findings of ECG and echocardiography are summarized in Table 1. An electrophysiology study was performed in 442 patients. Conduction system defect was present in 423 patients (49%), supraventricular arrhythmias in 75 patients (10%), and LV dysfunction in 75 patients (9%). Among patients with LV dysfunction, 40 (53%) were treated with angiotensin-converting enzyme inhibitors, 3 (4%) with angiotensin II receptor blockers, 19 (25%) with β-blockers, and 4 (5%) with diuretics. Of patients who suddenly died, 2 (6%) were treated with amiodarone, 2 (6%) with β-blockers, and 1 (3%) with antiarrhythmic agents class I.

Relationship Between CTG Expansion Size and Baseline Characteristics

Patient baseline characteristics and findings of ECG and echocardiography are presented in Table 1 for each CTG expansion size quartile.
Patients with larger mutations were significantly younger, had earlier onset of the disease, with more severe muscular involvement, higher Muscular disability Rating Scale score, and had more frequently diabetes mellitus. CTG expansion size was significantly correlated with heart rate \((R=0.148; P<0.0001)\). The prevalence of conduction system disease and left bundle branch block on the ECG was significantly higher, and PR and QRS intervals were longer in patients with larger mutation (Figure 1). No difference was observed for LV ejection fraction \((P=0.94)\) or the prevalence of LV systolic dysfunction \((P=0.44)\), supraventricular arrhythmias \((P=0.89)\), atrial fibrillation \((P=0.88)\), or premature ventricular contractions \((P=0.99)\).

The analysis of the relationship between patient characteristics at baseline and CTG expansion size, age, sex, and diabetes mellitus is presented in Table 2 in the Data Supplement. By multiple variable analysis, CTG expansion size was significantly associated with (1) all conduction defects on the ECG, including first-degree AV block, left and right bundle branch block, (2) LV systolic dysfunction, but not with PR and QRS intervals and LV ejection fraction on the echocardiography. Age and male sex were significantly associated with (1) conduction defects and more prolonged time intervals, (2) lower LV ejection fraction and LV dysfunction.

**Patient Outcome and Predictors of Cardiac Events**

Over a 11.5 (8.2–14.7) years median follow-up duration, 210 patients died (25%), including 68 from respiratory death and 32 suddenly, whose 8 (25%) ventricular arrhythmias were detected in 17 patients (2%), including 6 with pacemakers. Death from heart failure occurred in 12 patients (1%).

The lifetime incidence of death, sudden death, supraventricular arrhythmias, and implantations of pacemakers was significantly higher in patients with larger mutations. No difference was observed for sustained ventricular arrhythmias, whose incidence was by far lower than that for other end points (log rank, \(P=0.23\)).

The multiple variable analysis of the relationship between (1) CTG expansion size, age, sex, and diabetes mellitus, and (2) study end points is presented in Table 4. CTG expansion size was significantly associated with all end points except supraventricular arrhythmias. Each increase of 500 repeats in triplet expansion was associated with a 1.5-fold higher hazard of death from any causes. Age was associated with all end points and male sex, with total death, supraventricular arrhythmias, and pacemaker implantation. Diabetes mellitus was associated with total death and supraventricular arrhythmias.

The univariate and multivariate analyses of the relationship between (1) CTG expansion size and all other baseline characteristics, and (2) study end points are, respectively, shown in Table II in the Data Supplement and in Table 5. By multivariate analysis, (1) age, age of disease onset, male sex, CTG expansion size, and diabetes mellitus were associated with total death, (2) age and age of disease onset were associated with sudden death, (3) age, male sex, CTG expansion size, and supraventricular arrhythmia were associated with supraventricular arrhythmia, and (4) age, CTG expansion size, supraventricular arrhythmia, premature ventricular complexes, and any conduction defect were associated with pacemaker implantation.

**Discussion**

Our study shows a strong association between the size of the CTG expansion and the severity of cardiac involvement in DM1. We found a significant association between mutation size and (1) conduction defects on the ECG and LV dysfunction on echocardiography, (2) the occurrence of death of any cause, sudden death, and permanent pacemaker implantation in
| CTG Expansion Size | Total Population (n=855) | First Quartile <300 (n=228) | Second Quartile 300–530 (n=211) | Third Quartile 530–830 (n=207) | Fourth Quartile ≥830 (n=209) | P Value |
|-------------------|--------------------------|-----------------------------|-------------------------------|--------------------------------|-------------------------------|---------|
| **Age**           |                          | 37 (27–49)                  | 45 (34–56)                    | 32 (24–44)                     | 36 (26–45)                     | 37 (29–48) <0.001 |
| Male sex          |                          | 420 (49)                    | 109 (52)                      | 108 (52)                       | 101 (48)                       | 102 (44) 0.373 |
| **Age of disease onset** |                | 22 (14–35)                 | 32 (23–49)                    | 22 (16–35)                     | 19 (14–29)                     | 15 (10–30) <0.001 |
| MDRS              |                          | 3 (2–3)                     | 2 (2–3)                       | 2 (2–3)                        | 3 (2–3)                        | 3 (2–4) <0.001 |
| Diabetes mellitus |                          | 63 (7)                      | 10 (5)                        | 8 (4)                          | 20 (10)                        | 25 (11) 0.009 |
| **Personal medical history** |                    |                             |                               |                               |                               |         |
| Atrial fibrillation | 57 (7)                 | 13 (6)                      | 12 (6)                        | 15 (7)                         | 17 (7)                         | 0.884 |
| SVA               | 75 (10)                  | 16 (8)                      | 19 (9)                        | 18 (9)                         | 22 (10)                        | 0.89    |
| PVCs              | 53 (6)                   | 14 (7)                      | 13 (6)                        | 12 (6)                         | 14 (6)                         | 0.986 |
| **ECG**           |                          |                             |                               |                               |                               |         |
| Heart rate        | 68 (60–77)               | 66 (59–75)                  | 68 (60–74)                    | 69 (61–78)                     | 70 (61–81)                     | 0.001 |
| PR interval       | 185 (166–203)            | 181 (162–203)               | 181 (166–201)                 | 185 (166–200)                  | 192 (174–210)                  | 0.002 |
| QRS duration      | 96 (87–106)              | 94 (87–102)                 | 95 (86–105)                   | 95 (85–105)                    | 100 (90–111)                   | 0.001 |
| Any conduction defect | 423 (49)               | 95 (45)                     | 92 (44)                       | 96 (46)                        | 140 (61)                       | <0.001 |
| First-degree AV block | 268 (31)              | 64 (30)                     | 61 (29)                       | 58 (28)                        | 85 (37)                        | 0.143 |
| Left BBB          | 92 (11)                  | 17 (8)                      | 18 (9)                        | 17 (8)                         | 40 (18)                        | 0.002 |
| Right BBB         | 55 (6)                   | 9 (4)                       | 10 (5)                        | 18 (9)                         | 18 (8)                         | 0.173 |
| **Echocardiography** |                        |                             |                               |                               |                               |         |
| LVEF, %           | 65 (60–67)               | 64 (60–67)                  | 65 (60–67)                    | 64 (60–67)                     | 65 (60–68)                     | 0.939 |
| Mild              | 75 (9)                   | 16 (8)                      | 16 (8)                        | 3 (8)                          | 26 (11)                        | 0.435 |
| Moderate          | 59 (7)                   | 12 (5)                      | 13 (6)                        | 13 (6)                         | 21 (10)                        |         |
| Severe            | 14 (2)                   | 4 (2)                       | 3 (1)                         | 3 (1)                          | 4 (2)                          | 0.83   |
| LVEDD, mm         | 45 (42–49)               | 46 (43–49)*                 | 56 (42–49)                    | 45 (42–48)                     | 45 (42–48)                     | 0.029 |
| IVS, mm           | 8 (7–10)                 | 8 (7–10)                    | 8 (7–9)                       | 8 (7–10)                       | 9 (8–10)                       | 0.032 |
| PW, mm            | 8 (7–9)                  | 8 (7–9)                     | 7 (7–8)                       | 8 (7–9)                        | 8 (7–9)                        | 0.002 |
| End diastolic LV volume, mL | 92 (78–112) | 97 (87–112)* | 97 (83–112) | 92 (78–112) | 92 (78–107) | 0.001 |
| LV mass, g/m²     | 148 (121–184)            | 153 (127–190)               | 142 (116–179)                 | 146 (121–184)                  | 153 (119–180)                  | 0.09   |
| LV hypertrophy    | 160 (19)                 | 42 (21)                     | 26 (13)                       | 36 (18)                        | 56 (25)                        | 0.016 |
| **Cardiac device** |                        |                             |                               |                               |                               |         |
| Pacemaker         | 181 (21)                 | 44 (19)                     | 36 (17)                       | 37 (18)                        | 64 (31)                        | 0.020 |
| ICD               | 11 (1)                   | 2 (1)                       | 4 (2)                         | 2 (1)                          | 3 (1)                          | 0.789 |
| **Medical treatment** |                      |                             |                               |                               |                               |         |
| Amiodarone        | 29 (3)                   | 8 (4)                       | 9 (4)                         | 4 (2)                          | 8 (4)                          | 0.59   |
| Antiarrhythmic class I | 15 (2)                 | 1 (0.4)                     | 2 (1)                         | 6 (3)                          | 6 (3)                          | 0.14   |
| Beta-blockers     | 60 (7)                   | 18 (8)                      | 11 (5)                        | 11 (5)                         | 20 (10)                        | 0.29   |
| ACE inhibitor     | 61 (7)                   | 13 (6)                      | 10 (5)                        | 16 (8)                         | 22 (11)                        | 0.22   |
| ARB               | 9 (1)                    | 3 (1)                       | 3 (1)                         | 1 (0.5)                        | 2 (1)                          | 0.74   |
| Diuretic          | 4 (0.5)                  | 1 (0.4)                     | 1 (0.5)                       | 1 (0.5)                        | 1 (0.5)                        | 0.99   |
| Aspirin           | 31 (4)                   | 6 (4)                       | 5 (2)                         | 8 (4)                          | 12 (6)                         | 0.38   |
| Vitamin K antagonist | 35 (4)                 | 8 (4)                       | 10 (5)                        | 7 (3)                          | 10 (5)                         | 0.89   |

Values are median (quartile) or numbers (%) of observations. ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; AV, atrioventricular; BBB, bundle branch block; EF, ejection fraction; ICD, implantable cardioverter defibrillator; IVS, interventricular septum; LV, left ventricular; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; MDRS, Muscular Disability Rating Scale; PVC, premature ventricular complex; PW, posterior wall; and SVA, supraventricular arrhythmia.
Cardiac Genotype–Phenotype Correlations

Table 2. Multivariate Analysis of the Association Between CTG Expansion Size, Age, Sex, Diabetes Mellitus, and Baseline Characteristics

| Characteristic       | CTG Expansion Size | Age | Male Sex | Diabetes Mellitus |
|----------------------|-------------------|-----|----------|-------------------|
|                      | OR (95% CI)*      | P Value  | OR (95% CI)† | P Value          | OR (95% CI) | P Value          |
| Conduction defects   | 1.12 (1.08–1.17)  | <0.001 | 1.79 (1.59–2.01) | <0.001 | 1.84 (1.38–2.48) | <0.001 | 1.05 (0.59–1.86) | 0.87 |
| First-degree AV block | 1.06 (1.02–1.10)  | 0.0031 | 1.71 (1.51–1.93) | <0.001 | 1.73 (1.27–2.36) | 0.0005 | 1.14 (0.66–1.99) | 0.64 |
| Left BBB             | 1.11 (1.06–1.17)  | <0.001 | 1.83 (1.52–2.19) | <0.001 | 1.30 (0.82–2.06) | 0.26   | 0.91 (0.42–1.98) | 0.81 |
| Right BBB            | 1.06 (1.00–1.12)  | 0.049  | 1.31 (1.06–1.63) | 0.0124 | 1.91 (1.07–3.40) | 0.028  | 2.02 (0.92–4.45) | 0.08 |
| LV dysfunction       | 1.07 (1.02–1.13)  | <0.001 | 1.64 (1.35–1.99) | <0.001 | 3.47 (2.01–5.99) | <0.0001| 0.82 (0.35–1.93) | 0.65 |

BBB indicates bundle branch block; CI, confidence interval; LV, left ventricle; and OR, odds ratios.
*Odds ratios calculated with a step of 10 y.
†Odds ratios calculated with a step of 100 triplets.

Table 3. Incidence of Total Death, Sudden Death, and Cardiac Events

| Event               | Population (n=855) | CTG expansion size | First Quartile <300 (n=228) | Second Quartile 300–530 (n=211) | Third Quartile 530–830 (n=207) | Fourth Quartile ≥830 (n=209) |
|---------------------|-------------------|--------------------|-----------------------------|-----------------------------|--------------------------------|-----------------------------|
| Total death         | 210 (25)          | 47 (21)            | 40 (19)                     | 45 (22)                     | 78 (37)                        |                             |
| Sudden death        | 32 (4)            | 6 (3)              | 5 (2)                       | 7 (3)                       | 14 (7)                         |                             |
| SVA                 | 166 (19)          | 32 (14)            | 39 (18)                     | 40 (19)                     | 55 (26)                        |                             |
| Pacemaker implantation | 181 (21)      | 44 (19)            | 36 (17)                     | 37 (18)                     | 64 (31)                        |                             |
| Sustained VTA       | 17 (2)            | 4 (2)              | 2 (1)                       | 3 (1)                       | 8 (4)                          |                             |
| LV dysfunction      | 75 (9)            | 16 (7)             | 16 (8)                      | 17 (8)                      | 26 (12)                        |                             |

Values are numbers (%) of observations or median (quartile). LV indicates left ventricular, SVA, supraventricular arrhythmia; and VTA, ventricular tachyarrhythmias.
Cardiac Genotype–Phenotype Correlations during the life of DM1 patients, influencing, therefore, both onset and progression of the disease because the mutation size of the CTG tract may theoretically be higher in the heart than in the blood. However, correlations between CTG expansion size in heart tissues and cardiac dysfunctions have not been studied yet, probably because of low myocardial tissue availability. Nevertheless, our study shows that the expansion size measured on peripheral lymphocytes correlates significantly with clinical manifestations of the disease at the cardiac level.

**Conclusion**

In DM1, larger CTG amplification size is associated with the development of conduction system defect, LV dysfunction, supraventricular arrhythmias, sudden death, and total mortality.

**Table 4. Multivariate Analysis of the Correlation Between CTG Repeats, Age, Male Sex, Diabetes Mellitus, and Clinical Outcomes**

|                       | Total Death | Sudden Death | Supraventricular Arrhythmia | Pacemaker Implantation |
|-----------------------|-------------|--------------|----------------------------|------------------------|
|                       | HR (95% CI) | P Value      | HR (95% CI)                | P Value                |
| CTG repeats           | 1.49 (1.30–1.71) | <0.0001 | 1.53 (1.09–2.14) | 0.0130 | 1.15 (0.976–1.37) | 0.0939 | 1.32 (1.16–1.51) | <0.0001 |
| Age                   | 0.88 (0.86–0.90) | <0.0001 | 0.88 (0.82–0.93) | <0.0001 | 0.94 (0.92–0.96) | <0.0001 | 0.95 (0.94–0.97) | <0.0001 |
| Male sex              | 1.51 (1.14–1.99) | 0.0037 | 1.46 (0.72–2.96) | 0.29 | 1.82 (1.33–2.51) | 0.0002 | 1.37 (1.06–1.77) | 0.0164 |
| Diabetes mellitus     | 1.99 (1.37–2.89) | 0.0003 | 1.98 (0.75–5.25) | 0.17 | 1.98 (1.29–3.04) | 0.0019 | 1.12 (0.74–1.70) | 0.60 |

HR indicates hazard ratio.
*HR for CTG number are calculated for 500 CTG steps.
Table 5.  Multiple Variable Analysis of Association Between Baseline Characteristics and Clinical Outcomes

|                      | Total Death | Sudden Death | Supraventricular Arhythmia | Pacemaker Implantation |
|----------------------|-------------|--------------|---------------------------|------------------------|
|                      | Adjusted HR (95% CI) | P Value | Adjusted HR (95% CI) | P Value | Adjusted HR (95% CI) | P Value | Adjusted HR (95% CI) | P Value |
| Age, y               | 0.89 (0.86–0.91) | <0.0001 | 0.9 (0.84–0.96) | 0.0008 | 0.9 (0.88–0.92) | <0.0001 | 0.91 (0.90–0.93) | <0.0001 |
| Age of onset, y      | 0.98 (0.97–0.99) | 0.0032 | 0.96 (0.94–0.99) | 0.0060 | … | … | … | … |
| Male sex             | 1.54 (1.17–2.04) | 0.0023 | … | … | 1.52 (1.04–2.23) | 0.0324 | … | … |
| CTG expansion        | 1.39 (1.20–1.61) | <0.0001 | … | … | 1.25 (1.01–1.55) | 0.0423 | 1.24 (1.08–1.43) | 0.0032 |
| Diabetes mellitus    | 1.96 (1.35–2.84) | 0.0004 | … | … | … | … | … | … |
| Supraventricular arrhythmia | … | … | … | … | 16.3 (11.1–23.9) | <0.0001 | … | … |
| PVC                  | … | … | … | … | 4.31 (3.05–6.09) | <0.0001 | … | … |
| Any conduction defect| … | … | … | … | 8.49 (5.64–12.76) | <0.0001 | … | … |
| LV dysfunction       | … | … | … | … | … | … | … | … |

CI indicates confidence interval; HR, hazard ratio; LV, left ventricular; and PVC, premature ventricular complex.

Sources of Funding
This study was funded by grants from the Association Française contre les Myopathies (French Alliance Against Myopathies).

Disclosures
Arnaud Lazarus, MD, is a board member of Boston Scientific, a consultant for Sorin Group France, and an employee of Biotronik France. The other authors report no conflicts.

Appendix
From the Department of Cardiology, Cochin Hospital, APHP, Paris-Desertes, Sorbonne Paris Cité University, France (C.C.-N., K.W., D.D.); Department of Neurology, Myology Institute, Pitié-Salpêtrière Hospital, Paris, France (K.W., H.M.B., A.B., A.F., P.L., T.S., B.E., D.D.); Univ Paris-Sud, Paris-Saclay University, Le Kremlin Bicêtre, France (V.A.); Department of Cardiology, Antoine Béclère Hospital, APHP, Clamart, France; Inserm UMR S1180, Faculté de Pharmacie, Chatenay Malabry, France (V.A.); Laboratoire de Biochimie et Génétique moléculaire, Ambroise Paré Hospital, APHP, France (H.R.-H.); Genetic Department, Bichat Hospital, APHP, France (P.A.); Paris Diderot, Paris 7 University, France (P.A.); Inserm, CNRS, Centre de Recherche en Myologie, Institut de Myologie, Pitié-Salpêtrière Hospital, Sorbonne Universities UPMC Univ Paris 06, France (D.F.); InParys Clinical Research Group, Clinique Ambroise Paré, Neuilly, France (A.L., D.D.); Department of History, Henri-Mondor Hospital, APHP, France (G.B., P.L.); and Pierre et Marie Curie-Paris 6 University, France (B.E.).

References
1. Ashizawa T, Epstein HF. Ethnic distribution of myotonic dystrophy gene. 
Lancet. 1991;338:642–643.
2. Mahadevan M, Tsiflidis C, Sabourin L, Shutter G, Amemiya C, Jansen G, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3’ untranslated region of the gene. Science. 1992;255:1253–1255.
3. Breton R, Mathieu J. Usefulness of clinical and electrocardiographic data for predicting adverse cardiac events in patients with myotonic dystrophy. 
Can J Cardiol. 2009;25:e23–e27.
4. Wahlb K, Meune C, Porcher R, Bécane HM, Lazarus A, Lafont P, et al. Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease. 
JAMA. 2012;307:1292–1301. doi: 10.1001/jama.2012.346.
5. New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium (IDMC). 
Neurology. 2000;54:1218–1221.
6. Kamsteeg EJ, Kress W, Catali C, Hertz JM, Witsch-Baumgartner M, Buckley MF, et al. Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2. Eur J Hum Genet. 2012;20:1203–1208. doi: 10.1038/ejhg.2012.108.
7. Tsiflidis C, MacKenzie AE, Mettler G, Barceló J, Korneluk RG. Correlation between CTG trinucleotide repeat length and frequency of severe congenital myotonic dystrophy. 
Nat Genet. 1992;1:192–195. doi: 10.1038/ng0692-192.
8. Redman JB, Fenwick RG Jr, Fu YH, Pizzuti A, Caskey CT. Relationship between parental trinucleotide CCG repeat length and severity of myotonic dystrophy in offspring. 
JAMA. 1993;269:1960–1965.
9. Groh WJ, Lowe MR, Zipes DP. Severity of cardiac conduction involve-
ment and arrhythmias in myotonic dystrophy type 1 correlates with age and CTG repeat length. 
J Cardiovasc Electrophysiol. 2002;13:444–448.
10. Clarke NR, Kelion AD, Nixon J, Hilton-Jones D, Forfar JC. Does cytosine-thymine-guanine (CTG) expansion size predict cardiac events and electrocardiographic progression in myotonic dystrophy? 
Heart. 2001;86:411–416.
11. Lazarus A, Varin J, Ounneghene Z, Radvanyi H, Junien C, Coste J, et al. Relationships among electrophysiological findings and clinical status, heart function, and extent of DNA mutation in myotonic dystrophy. 
Circulation. 1999;99:1041–1046.
12. Antonini G, Giubilei F, Mammarella A, Amicucci P, Fiorelli M, Gragnani F, et al. Natural history of cardiac involvement in myotonic dystrophy: correlation with CTG repeats. 
Neurology. 2000;55:1207–1209.
13. Groh WJ, Groh MR, Shen C, Monckton DG, Bodkin CL, Pascuzzi RM. Survival and CTG repeat expansion in adults with myotonic dystrophy type 1. Muscle Nerve. 2011;43:648–651. doi: 10.1002/mus.21934.
14. Melacini P, Villanova C, Menegazzo E, Novelli G, Danieli G, Rizzoli G, et al. Correlation between cardiac involvement and CTG trinucleotide repeat length in myotonic dystrophy. 
J Am Coll Cardiol. 1995;25:239–245.
15. Surawicz B, Childers R, Deal BJ, Gettes LS, Bailey JJ, Gorges A, et al; American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation; Heart Rhythm Society. AHA/ACC/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. 
Circulation. 2009;119:e235–e240. doi: 10.1161/CIRCULATIONAHA.108.191095.
16. Cheiltin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, et al; ACC; AHA; ASE; ACC/AHA/ASE 2005 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocar-
diography). 
J Am Soc Echocardiogr. 2003;16:1091–1110. doi: 10.1016/S0894-7317(03)00685-0.
Myotonic dystrophy type 1, the most common neuromuscular disease in adults, is caused by the expansion of a (CTG)n triplet repeat in the DMPK gene. In our study, which included 855 patients, expansion size was significantly correlated with the presence of conduction defects on the ECG and left ventricular systolic dysfunction at initial presentation, independently to age, sex, or diabetes mellitus. Expansion size was also independently associated, over a median 11.5 years follow-up period, with total mortality, conduction defects requiring permanent pacing, and supraventricular arrhythmias in a model, including all patient characteristics at initial presentation. These results suggest that expansion size is independently associated with the severity of cardiac involvement in myotonic dystrophy type 1.
Association Between Mutation Size and Cardiac Involvement in Myotonic Dystrophy Type 1: An Analysis of the DM1-Heart Registry

Caroline Chong-Nguyen, Karim Wahbi, Vincent Algalarrondo, Henri Marc Bécane, Hélène Radvanyi-Hoffman, Pauline Arnaud, Denis Furling, Arnaud Lazarus, Guillaume Bassez, Anthony Béhin, Abdallah Fayssoil, Pascal Laforêt, Tanya Stojkovic, Bruno Eymard and Denis Duboc

Circ Cardiovasc Genet. 2017;10:
doi: 10.1161/CIRCGENETICS.116.001526

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circgenetics.ahajournals.org/content/10/3/e001526

Data Supplement (unedited) at:
http://circgenetics.ahajournals.org/content/suppl/2017/06/13/CIRCGENETICS.116.001526.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Genetics can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Cardiovascular Genetics is online at:
http://circgenetics.ahajournals.org//subscriptions/
**SUPPLEMENTAL MATERIAL**

**Supplemental Table 1:** Multivariate analysis of the association between CTG expansion size, age, gender, diabetes and baseline ECG and echocardiography findings.

|                      | CTG expansion size | Age     | Male gender | Diabetes |
|----------------------|--------------------|---------|-------------|----------|
|                      | F      | P     | F      | P     | F      | P     | F      | P     |
| PR interval          | 0.07   | 0.79  | 6.52   | 0.011 | 2.52   | 0.11  | 0.94   | 0.33  |
| QRS interval         | 0.06   | 0.79  | 1.42   | 0.23  | 5.48   | 0.020 | 0.38   | 0.54  |
| LV ejection fraction (%) | 0.31 | 0.58  | 0.45   | 0.50  | 0.58   | 0.45  | 0.53   | 0.47  |

Abbreviations: LV: left ventricular.

*F: adjusted variance ratio
**Supplemental Table 2:** Single variable analysis of association between baseline characteristics and clinical outcomes

|                                | Total death | Sudden death | Supraventricular arrhythmia | Pacemaker implantation |
|--------------------------------|-------------|--------------|-----------------------------|------------------------|
|                                | Adjusted HR (95% CI) | P     | Adjusted HR (95% CI) | P     | Adjusted HR (95% CI) | P     | Adjusted HR (95% CI) | P     |
| Age (years)                    | 0.88 (0.86 to 0.90) | <0.0001 | 0.87 (0.82 to 0.93) | <0.0001 | 0.95 (0.93 to 0.97) | <0.0001 | 0.95 (0.94 to 0.96) | <0.0001 |
| Age of onset (years)           | 0.96 (0.96 to 0.97) | <0.0001 | 0.95 (0.93 to 0.97) | <0.0001 | 0.98 (0.97 to 0.99) | 0.0053 | 0.98 (0.97 to 0.98) | <0.0001 |
| Sex: Male                      | 1.42 (1.08 to 1.87) | 0.0121 | 1.41 (0.70 to 2.85) | 0.34 | 1.89 (1.31 to 2.74) | 0.0007 | 1.25 (0.97 to 1.61) | 0.0862 |
| CTG expansion (500 CTG)        | 1.56 (1.39 to 1.75) | <0.0001 | 1.60 (1.20 to 2.12) | 0.0012 | 1.21 (1.02 to 1.44) | 0.029 | 1.37 (1.21 to 1.55) | <0.0001 |
| Diabetes                       | 2.14 (1.48 to 3.08) | <0.0001 | 1.97 (0.76 to 5.14) | 0.16 | 1.63 (0.99 to 2.69) | 0.0557 | 1.18 (0.79 to 1.78) | 0.42 |
| Supraventricular arrhythmia    | 0.94 (0.63 to 1.38) | 0.74 | 1.52 (0.46 to 5.04) | 0.50 | 10.7 (7.5 to 15.3) | <0.0001 | 2.04 (1.46 to 2.86) | <0.0001 |
| PVC                            | 0.74 (0.44 to 1.23) | 0.24 | 0.63 (0.15 to 2.63) | 0.52 | 1.59 (0.92 to 2.72) | 0.095 | 3.38 (2.44 to 4.67) | <0.0001 |
| Any Conduction defect          | 1.37 (1.01 to 1.86) | 0.043 | 1.46 (0.67 to 3.19) | 0.34 | 3.26 (2.05 to 5.18) | <0.0001 | 6.23 (4.20 to 9.24) | <0.0001 |
| LV dysfunction                 | 1.34 (0.93 to 1.94) | 0.12 | 1.39 (0.53 to 3.64) | 0.51 | 1.8 (1.14 to 2.84) | 0.0111 | 1.68 (1.20 to 2.36) | 0.0028 |

Abbreviations: LV: LV dysfunction; PVC: premature ventricular complex
Supplemental Figure 1: Distribution of the number of CTG repeats in the DM1 Heart Registry. Additional bars delimitate the median (full line) and the 25/75th quartiles (dotted lines). The quartiles (Q1-Q4) are represented accordingly.